^
    Back
    Association details:
    Biomarker:KRAS wild-type
    Cancer:Rectal Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Rectal cancer: Systemic therapy for advanced or metastatic disease...FOLFOX + Cetuximab (KRAS/NRAS/BRAF WT only)...FOLFIRI + cetuximab (KRAS/NRAS/BRAF WT only)...FOLFIRINOX or mFOLFIRINOX + cetuximab...Irinotecan + cetuximab (KRAS/NRAS/BRAF WT only)
    Secondary therapy:
    FOLFOX; ; FOLFIRI; irinotecan
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer

    Excerpt:
    ...eligible malignancies include: colorectal cancer KRAS wild-type and squamous cell head and neck cancer...
    Trial ID:
    NCT01254617
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery

    Excerpt:
    ...- Although KRAS status will be evaluated in the tumor, wild type KRAS status is...
    Trial ID:
    NCT00835679
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    Multicenter prospective single-arm study investigating the efficacy and safety of second-line cetuximab plus chemotherapy treatment in initially RAS-mt mCRC patients who converted to RAS-wt at the time of first progression Studio di fase II a singolo braccio di terapia di II linea con cetuximab e chemioterapia in pazienti con carcinoma colorettale metastatico KRAS e NRAS mutato alla diagnosi con assenza di mutazioni di KRAS/NRAS su plasma alla progressione da prima linea

    Excerpt:
    ...• Consenso informato scritto nella fase di screening e nella fase di arruolamento• KRAS/NRAS wild-type su plasma (DNA tumorale circolante) al momento della progressione da prima linea di trattamento• Aspettativa di vita di almeno 3 mesi...
    Trial ID:
    2019-001328-36
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrialsregister.eu
    Title:

    A prospective, single-arm, exploratory clinical study on the combination of long-course chemoradiotherapy with PD1 monoclonal antibody and cetuximab for preoperative neoadjuvant therapy of locally advanced middle and low rectal cancer

    Excerpt:
    ......
    Trial ID:
    ChiCTR2500105882